相似文献
1
Proliferative Vitreoretinopathy: A Review.
Int Ophthalmol Clin. 2019 Winter;59(1):221-240. doi: 10.1097/IIO.0000000000000258.
2
Adjunctive therapies for proliferative vitreoretinopathy.
Int Ophthalmol Clin. 2004 Summer;44(3):1-10. doi: 10.1097/00004397-200404430-00003.
3
Intravitreal bevacizumab (avastin) combined with vitrectomy for recurrences of proliferative vitreoretinopathy in Von Hippel-Lindau disease.
Acta Ophthalmol. 2012 Mar;90(2):e157-8. doi: 10.1111/j.1755-3768.2011.02108.x. Epub 2011 Jun 8.
4
Diagnostic and Therapeutic Challenges.
Retina. 2015 Dec;35(12):2657-9. doi: 10.1097/IAE.0000000000000481.
5
Patomechanisms in proliferative vitreoretinopathy.
Klin Oczna. 2011;113(1-3):64-7.
6
VEGF inhibitors and vitrectomy for diabetic vitreoretinopathy.
Dev Ophthalmol. 2009;44:69-81. doi: 10.1159/000223947. Epub 2009 Jun 3.
7
[Proliferative Vitreoretinopathy: Therapeutic Strategies].
Klin Monbl Augenheilkd. 2016 Sep;233(9):1016-23. doi: 10.1055/s-0042-107947. Epub 2016 Aug 1.
8
Long-term clinical outcomes and therapeutic benefits of triamcinolone-assisted pars plana vitrectomy for proliferative vitreoretinopathy: a case study.
Eur J Ophthalmol. 2007 May-Jun;17(3):392-8. doi: 10.1177/112067210701700320.
9
Perioperative anti-vascular endothelial growth factor agents treatment in patients undergoing vitrectomy for complicated proliferative diabetic retinopathy: a network meta-analysis.
Sci Rep. 2020 Nov 3;10(1):18880. doi: 10.1038/s41598-020-75896-8.
10
Proliferative vitreoretinopathy: pathobiology and therapeutic targets.
Semin Ophthalmol. 2009 Mar-Apr;24(2):62-9. doi: 10.1080/08820530902800082.
引用本文的文献
1
MyoD is required for the differentiation of Myo/Nog cell progenitors of myofibroblasts in explants of human lens tissue.
Front Ophthalmol (Lausanne). 2025 Aug 4;5:1618276. doi: 10.3389/fopht.2025.1618276. eCollection 2025.
2
Mammalian Target Rapamycin Inhibition as a Therapeutic Target for Prevention of Proliferative Vitreoretinopathy.
JAMA Ophthalmol. 2025 Aug 7. doi: 10.1001/jamaophthalmol.2025.2497.
3
Epigenetic Modifications in the Retinal Pigment Epithelium of the Eye During RPE-Related Regeneration or Retinal Diseases in Vertebrates.
Biomedicines. 2025 Jun 25;13(7):1552. doi: 10.3390/biomedicines13071552.
4
Removal of subretinal strands without creating an intentional retinal hole: A case report.
Am J Ophthalmol Case Rep. 2025 Jul 12;39:102388. doi: 10.1016/j.ajoc.2025.102388. eCollection 2025 Sep.
5
Inflammatory Mechanisms in the Management and Treatment of Retinal Detachment.
Metabolites. 2025 Jul 1;15(7):442. doi: 10.3390/metabo15070442.
6
A multicenter study on rates and risk factors of proliferative vitreoretinopathy in a low-income economy.
PLoS One. 2025 Jul 24;20(7):e0316058. doi: 10.1371/journal.pone.0316058. eCollection 2025.
7
Long-Term Cannabis Use and Risk of Postoperative Proliferative Vitreoretinopathy.
JAMA Ophthalmol. 2025 Jul 3. doi: 10.1001/jamaophthalmol.2025.1851.
8
Liposome Encapsulation Enhances Ripasudil Therapeutic Efficacy Against Proliferative Vitreoretinal Diseases: Implications in Advanced Ocular Treatment.
Invest Ophthalmol Vis Sci. 2025 Jun 2;66(6):56. doi: 10.1167/iovs.66.6.56.
9
Shedding light on the cell biology and diverse physiological functions of the migrasome.
Cell Biosci. 2025 May 28;15(1):70. doi: 10.1186/s13578-025-01417-7.
10
Incidence and risk factors for recurrence after surgical treatment of rhegmatogenous retinal detachment: a retrospective cohort study.
Int J Retina Vitreous. 2025 May 22;11(1):59. doi: 10.1186/s40942-025-00680-7.
本文引用的文献
1
Internal Limiting Membrane Peeling in Macula-off Retinal Detachment Complicated by Grade B Proliferative Vitreoretinopathy.
Am J Ophthalmol. 2018 Jul;191:1-6. doi: 10.1016/j.ajo.2018.03.037. Epub 2018 Apr 3.
2
Long-Term Visual Outcomes and Safety Profile of 27-Gauge Pars Plana Vitrectomy for Posterior Segment Disease.
Ophthalmology. 2018 Mar;125(3):423-431. doi: 10.1016/j.ophtha.2017.09.013. Epub 2017 Nov 13.
3
Effect of Methotrexate on an In Vitro Patient-Derived Model of Proliferative Vitreoretinopathy.
Invest Ophthalmol Vis Sci. 2017 Aug 1;58(10):3940-3949. doi: 10.1167/iovs.16-20912.
4
Inhibition of Proliferation and Epithelial Mesenchymal Transition in Retinal Pigment Epithelial Cells by Heavy Chain-Hyaluronan/Pentraxin 3.
Sci Rep. 2017 Mar 2;7:43736. doi: 10.1038/srep43736.
5
Slow-Release Dexamethasone in Proliferative Vitreoretinopathy: A Prospective, Randomized Controlled Clinical Trial.
Ophthalmology. 2017 Jun;124(6):757-767. doi: 10.1016/j.ophtha.2017.01.021. Epub 2017 Feb 23.
6
SMOKING IS A RISK FACTOR FOR PROLIFERATIVE VITREORETINOPATHY AFTER TRAUMATIC RETINAL DETACHMENT.
Retina. 2017 Jul;37(7):1229-1235. doi: 10.1097/IAE.0000000000001361.
7
Intravitreal methotrexate infusion for proliferative vitreoretinopathy.
Clin Ophthalmol. 2016 Sep 19;10:1811-1817. doi: 10.2147/OPTH.S111893. eCollection 2016.
8
Intravitreal Injection of Bevacizumab in Primary Vitrectomy to Decrease the Rate of Retinal Redetachment: A Randomized Pilot Study.
J Ophthalmic Vis Res. 2016 Jul-Sep;11(3):271-6. doi: 10.4103/2008-322X.188390.
9
Internal Limiting Membrane Peeling to Prevent Post-vitrectomy Epiretinal Membrane Development in Retinal Detachment.
Am J Ophthalmol. 2016 Nov;171:1-10. doi: 10.1016/j.ajo.2016.08.015. Epub 2016 Aug 18.
10
Classifications for Proliferative Vitreoretinopathy (PVR): An Analysis of Their Use in Publications over the Last 15 Years.
J Ophthalmol. 2016;2016:7807596. doi: 10.1155/2016/7807596. Epub 2016 Jun 27.
Zotero 插件